We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > RYGB

News List

Bariatric Surgery Cuts Hepatic Steatosis in Obesity and T2DM Drugs
November 30, 2021
Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are highly effective for reducing hepatic steatosis in patients with severe obesity and type 2 diabetes, with almost complete clearance of liver fat one year after surgery...
Interventions More Likely After RYGB Versus Sleeve Gastrectomy drugs
January 16, 2020
Among adults undergoing bariatric surgery, interventions, operations, and hospitalizations are more likely after Roux en Y gastric bypass (RYGB) than after sleeve gastrectomy (SG), according to a study published online Jan. 15 in JAMA Surgery.
Gastric Sleeve Tied to Lower Risk for Subsequent Procedures drugs
December 31, 2019
Patients undergoing vertical sleeve gastrectomy (VSG) appear to be less likely than matched patients undergoing Roux-en-Y gastric bypass (RYGB) to experience subsequent abdominal operative interventions ...